| Ticker | Action | Number of Shares Bought/Sold | Value of Shares Added/Sold | Average Price paid for previous share BUYs |
|---|
| 2413.T - M3, Inc. | HOLD | 0 @ JPY 16.9442 | JPY 0 | The current share valuation price of 2413.T based on adjusted close was JPY 16.9442. The average price that 2413.T shares were previous bought at was JPY 14.4368. The current market price is 17.4% higher than average price they were purchased at. The value of the holding in 2413.T has increased by JPY 9,910 (USD $63) compared to the previous valuation of M3, Inc. however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| 4151.T - Kyowa Kirin Co., Ltd. | HOLD | 0 @ JPY 16.9666 | JPY 0 | The current share valuation price of 4151.T based on adjusted close was JPY 16.9666. The average price that 4151.T shares were previous bought at was JPY 15.6831. The current market price is 8.2% higher than average price they were purchased at. The value of the holding in 4151.T has increased by JPY 5,084 (USD $33) compared to the previous valuation of Kyowa Kirin Co., Ltd. however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| 4502.T - Takeda Pharmaceutical Company Limited | HOLD | 0 @ JPY 28.9915 | JPY 0 | The current share valuation price of 4502.T based on adjusted close was JPY 28.9915. The average price that 4502.T shares were previous bought at was JPY 28.7792. The current market price is 0.7% higher than average price they were purchased at. The value of the holding in 4502.T has increased by JPY 15,061 (USD $96) compared to the previous valuation of Takeda Pharmaceutical Company Limited however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| 4503.T - Astellas Pharma Inc. | HOLD | 0 @ JPY 12.677 | JPY 0 | The current share valuation price of 4503.T based on adjusted close was JPY 12.677. The average price that 4503.T shares were previous bought at was JPY 10.8216. The current market price is 17.1% higher than average price they were purchased at. The value of the holding in 4503.T has increased by JPY 5,180 (USD $33) compared to the previous valuation of Astellas Pharma Inc. however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| 4507.T - Shionogi & Co., Ltd. | HOLD | 0 @ JPY 17.6443 | JPY 0 | The current share valuation price of 4507.T based on adjusted close was JPY 17.6443. The average price that 4507.T shares were previous bought at was JPY 16.8914. The current market price is 4.5% higher than average price they were purchased at. The value of the holding in 4507.T has increased by JPY 2,207 (USD $14) compared to the previous valuation of Shionogi & Co., Ltd. however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| 4519.T - Chugai Pharmaceutical Co., Ltd. | HOLD | 0 @ JPY 54.7483 | JPY 0 | The current share valuation price of 4519.T based on adjusted close was JPY 54.7483. The average price that 4519.T shares were previous bought at was JPY 46.605. The current market price is 17.5% higher than average price they were purchased at. The value of the holding in 4519.T has increased by JPY 98,943 (USD $633) compared to the previous valuation of Chugai Pharmaceutical Co., Ltd. however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| 4523.T - Eisai Co., Ltd. | HOLD | 0 @ JPY 32.1624 | JPY 0 | The current share valuation price of 4523.T based on adjusted close was JPY 32.1624. The average price that 4523.T shares were previous bought at was JPY 30.3804. The current market price is 5.9% higher than average price they were purchased at. The value of the holding in 4523.T has fallen by JPY 453 (USD $3) compared to the previous valuation of Eisai Co., Ltd. |
| 4543.T - Terumo Corporation | HOLD | 0 @ JPY 15.7711 | JPY 0 | The current share valuation price of 4543.T based on adjusted close was JPY 15.7711. The average price that 4543.T shares were previous bought at was JPY 16.5774. The current market price is -4.9% lower than average price they were purchased at. The value of the holding in 4543.T has increased by JPY 5,854 (USD $37) compared to the previous valuation of Terumo Corporation however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| 4568.T - Daiichi Sankyo Company, Limited | HOLD | 0 @ JPY 24.6891 | JPY 0 | The current share valuation price of 4568.T based on adjusted close was JPY 24.6891. The average price that 4568.T shares were previous bought at was JPY 24.0746. The current market price is 2.6% higher than average price they were purchased at. The value of the holding in 4568.T has increased by JPY 35,190 (USD $225) compared to the previous valuation of Daiichi Sankyo Company, Limited however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| 4578.T - Otsuka Holdings Co., Ltd. | HOLD | 0 @ JPY 57.7082 | JPY 0 | The current share valuation price of 4578.T based on adjusted close was JPY 57.7082. The average price that 4578.T shares were previous bought at was JPY 53.3755. The current market price is 8.1% higher than average price they were purchased at. The value of the holding in 4578.T has increased by JPY 20,704 (USD $133) compared to the previous valuation of Otsuka Holdings Co., Ltd. however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| 6869.T - Sysmex Corporation | HOLD | 0 @ JPY 9.82899 | JPY 0 | The current share valuation price of 6869.T based on adjusted close was JPY 9.82899. The average price that 6869.T shares were previous bought at was JPY 12.4691. The current market price is -21.2% lower than average price they were purchased at. The value of the holding in 6869.T has fallen by JPY 40,200 (USD $257) compared to the previous valuation of Sysmex Corporation |
| 7733.T - Olympus Corporation | HOLD | 0 @ JPY 13.5273 | JPY 0 | The current share valuation price of 7733.T based on adjusted close was JPY 13.5273. The average price that 7733.T shares were previous bought at was JPY 12.6037. The current market price is 7.3% higher than average price they were purchased at. The value of the holding in 7733.T has increased by JPY 3,484 (USD $22) compared to the previous valuation of Olympus Corporation however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| 7741.T - HOYA Corporation | HOLD | 0 @ JPY 151.191 | JPY 0 | The current share valuation price of 7741.T based on adjusted close was JPY 151.191. The average price that 7741.T shares were previous bought at was JPY 145.222. The current market price is 4.1% higher than average price they were purchased at. The value of the holding in 7741.T has increased by JPY 32,143 (USD $206) compared to the previous valuation of HOYA Corporation however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| A - Agilent Technologies Inc | HOLD | 0 @ USD 154.37 | USD 0 | The current share valuation price of A based on adjusted close was USD 154.37. The average price that A shares were previous bought at was USD 134.498. The current market price is 14.8% higher than average price they were purchased at. The value of the holding in A has fallen by USD 154,973 compared to the previous valuation of Agilent Technologies Inc |
| ABBV - AbbVie Inc | HOLD | 0 @ USD 227.66 | USD 0 | The current share valuation price of ABBV based on adjusted close was USD 227.66. The average price that ABBV shares were previous bought at was USD 206.46. The current market price is 10.3% higher than average price they were purchased at. The value of the holding in ABBV has fallen by USD 596,852 compared to the previous valuation of AbbVie Inc |
| ABT - Abbott Laboratories | HOLD | 0 @ USD 128.54 | USD 0 | The current share valuation price of ABT based on adjusted close was USD 128.54. The average price that ABT shares were previous bought at was USD 131.614. The current market price is -2.3% lower than average price they were purchased at. The value of the holding in ABT has increased by USD 42,567 compared to the previous valuation of Abbott Laboratories however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| ALC.SW - | HOLD | 0 @ CHF 79.3893 | CHF 0 | The current share valuation price of ALC.SW based on adjusted close was CHF 79.3893. The average price that ALC.SW shares were previous bought at was CHF 77.7293. The current market price is 2.1% higher than average price they were purchased at. The value of the holding in ALC.SW has increased by CHF 89,284 (USD $110,503) compared to the previous valuation of however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| ALNY - Alnylam Pharmaceuticals Inc | HOLD | 0 @ USD 445.12 | USD 0 | The current share valuation price of ALNY based on adjusted close was USD 445.12. The average price that ALNY shares were previous bought at was USD 420.306. The current market price is 5.9% higher than average price they were purchased at. The value of the holding in ALNY has increased by USD 159,374 compared to the previous valuation of Alnylam Pharmaceuticals Inc however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| AMGN - Amgen Inc | HOLD | 0 @ USD 344.57 | USD 0 | The current share valuation price of AMGN based on adjusted close was USD 344.57. The average price that AMGN shares were previous bought at was USD 302.352. The current market price is 14.0% higher than average price they were purchased at. The value of the holding in AMGN has increased by USD 124,456 compared to the previous valuation of Amgen Inc however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| ARGX.BR - Argenx SE | HOLD | 0 @ EUR 924.187 | EUR 0 | The current share valuation price of ARGX.BR based on adjusted close was EUR 924.187. The average price that ARGX.BR shares were previous bought at was EUR 847.148. The current market price is 9.1% higher than average price they were purchased at. The value of the holding in ARGX.BR has increased by EUR 74,585 (USD $86,256) compared to the previous valuation of Argenx SE however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| AZN.L - AstraZeneca PLC | HOLD | 0 @ GBP 187.143 | GBP 0 | The current share valuation price of AZN.L based on adjusted close was GBP 187.143. The average price that AZN.L shares were previous bought at was GBP 159.117. The current market price is 17.6% higher than average price they were purchased at. The value of the holding in AZN.L has increased by GBP 192,857 (USD $253,775) compared to the previous valuation of AstraZeneca PLC however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| BAX - Baxter International Inc | HOLD | 0 @ USD 18.91 | USD 0 | The current share valuation price of BAX based on adjusted close was USD 18.91. The average price that BAX shares were previous bought at was USD 19.5935. The current market price is -3.5% lower than average price they were purchased at. The value of the holding in BAX has increased by USD 3,780 compared to the previous valuation of Baxter International Inc however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| BAYN.DE - Bayer AG | HOLD | 0 @ EUR 35.1872 | EUR 0 | The current share valuation price of BAYN.DE based on adjusted close was EUR 35.1872. The average price that BAYN.DE shares were previous bought at was EUR 31.4423. The current market price is 11.9% higher than average price they were purchased at. The value of the holding in BAYN.DE has fallen by EUR 9,004 (USD $10,413) compared to the previous valuation of Bayer AG |
| BDX - Becton Dickinson and Company | HOLD | 0 @ USD 193.9 | USD 0 | The current share valuation price of BDX based on adjusted close was USD 193.9. The average price that BDX shares were previous bought at was USD 183.347. The current market price is 5.8% higher than average price they were purchased at. The value of the holding in BDX has fallen by USD 9,728 compared to the previous valuation of Becton Dickinson and Company |
| BIIB - Biogen Inc | HOLD | 0 @ USD 181.94 | USD 0 | The current share valuation price of BIIB based on adjusted close was USD 181.94. The average price that BIIB shares were previous bought at was USD 173.846. The current market price is 4.7% higher than average price they were purchased at. The value of the holding in BIIB has fallen by USD 178 compared to the previous valuation of Biogen Inc |
| BIM.PA - BioMerieux | HOLD | 0 @ EUR 127.49 | EUR 0 | The current share valuation price of BIM.PA based on adjusted close was EUR 127.49. The average price that BIM.PA shares were previous bought at was EUR 127.24. The current market price is 0.2% higher than average price they were purchased at. The value of the holding in BIM.PA has increased by EUR 1,720 (USD $1,989) compared to the previous valuation of BioMerieux however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| BMY - Bloomsbury Publishing Plc | HOLD | 0 @ USD 49.25 | USD 0 | The current share valuation price of BMY based on adjusted close was USD 49.25. The average price that BMY shares were previous bought at was USD 47.3663. The current market price is 4.0% higher than average price they were purchased at. The value of the holding in BMY has increased by USD 24,630 compared to the previous valuation of Bloomsbury Publishing Plc however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| BSX - Boston Scientific Corporation | HOLD | 0 @ USD 100.96 | USD 0 | The current share valuation price of BSX based on adjusted close was USD 100.96. The average price that BSX shares were previous bought at was USD 101.156. The current market price is -0.2% lower than average price they were purchased at. The value of the holding in BSX has fallen by USD 13,222 compared to the previous valuation of Boston Scientific Corporation |
| BSX - MULSTRXSSXIMETFP | HOLD | 0 @ USD 100.96 | USD 0 | The current share valuation price of BSX based on adjusted close was USD 100.96. The average price that BSX shares were previous bought at was USD 101.156. The current market price is -0.2% lower than average price they were purchased at. The value of the holding in BSX has fallen by USD 13,222 compared to the previous valuation of MULSTRXSSXIMETFP |
| CAH - Cardinal Health Inc | HOLD | 0 @ USD 213.14 | USD 0 | The current share valuation price of CAH based on adjusted close was USD 213.14. The average price that CAH shares were previous bought at was USD 167.417. The current market price is 27.3% higher than average price they were purchased at. The value of the holding in CAH has fallen by USD 28,625 compared to the previous valuation of Cardinal Health Inc |
| CI - Cigna Corp | HOLD | 0 @ USD 278.35 | USD 0 | The current share valuation price of CI based on adjusted close was USD 278.35. The average price that CI shares were previous bought at was USD 291.006. The current market price is -4.3% lower than average price they were purchased at. The value of the holding in CI has increased by USD 5,397 compared to the previous valuation of Cigna Corp however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| CNC - Concurrent Technologies Plc | HOLD | 0 @ USD 39.46 | USD 0 | The current share valuation price of CNC based on adjusted close was USD 39.46. The average price that CNC shares were previous bought at was USD 38.4416. The current market price is 2.6% higher than average price they were purchased at. The value of the holding in CNC has fallen by USD 18,371 compared to the previous valuation of Concurrent Technologies Plc |
| COH.AX - | HOLD | 0 @ AUD 181.753 | AUD 0 | The current share valuation price of COH.AX based on adjusted close was AUD 181.753. The average price that COH.AX shares were previous bought at was AUD 185.819. The current market price is -2.2% lower than average price they were purchased at. The value of the holding in COH.AX has increased by AUD 99,748 (USD $64,540) compared to the previous valuation of however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| COLO-B.CO - | HOLD | 0 @ DKK 90.4718 | DKK 0 | The current share valuation price of COLO-B.CO based on adjusted close was DKK 90.4718. The average price that COLO-B.CO shares were previous bought at was DKK 92.2349. The current market price is -1.9% lower than average price they were purchased at. The value of the holding in COLO-B.CO has fallen by DKK 21,820 (USD $3,379) compared to the previous valuation of |
| COO - The Cooper Companies, Inc. Common Stock | HOLD | 0 @ USD 77.94 | USD 0 | The current share valuation price of COO based on adjusted close was USD 77.94. The average price that COO shares were previous bought at was USD 75.6989. The current market price is 3.0% higher than average price they were purchased at. The value of the holding in COO has fallen by USD 4,996 compared to the previous valuation of The Cooper Companies, Inc. Common Stock |
| COR - Cencora Inc. | HOLD | 0 @ USD 368.53 | USD 0 | The current share valuation price of COR based on adjusted close was USD 368.53. The average price that COR shares were previous bought at was USD 320.421. The current market price is 15.0% higher than average price they were purchased at. The value of the holding in COR has fallen by USD 225,755 compared to the previous valuation of Cencora Inc. |
| CSL.AX - | HOLD | 0 @ AUD 119.068 | AUD 0 | The current share valuation price of CSL.AX based on adjusted close was AUD 119.068. The average price that CSL.AX shares were previous bought at was AUD 120.123. The current market price is -0.9% lower than average price they were purchased at. The value of the holding in CSL.AX has increased by AUD 41,863 (USD $27,087) compared to the previous valuation of however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| CVS - CVS Health Corp | HOLD | 0 @ USD 79.86 | USD 0 | The current share valuation price of CVS based on adjusted close was USD 79.86. The average price that CVS shares were previous bought at was USD 71.1294. The current market price is 12.3% higher than average price they were purchased at. The value of the holding in CVS has increased by USD 103,154 compared to the previous valuation of CVS Health Corp however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| DEMANT.CO - | HOLD | 0 @ DKK 33.923 | DKK 0 | The current share valuation price of DEMANT.CO based on adjusted close was DKK 33.923. The average price that DEMANT.CO shares were previous bought at was DKK 35.87. The current market price is -5.4% lower than average price they were purchased at. The value of the holding in DEMANT.CO has increased by DKK 1,856 (USD $287) compared to the previous valuation of however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| DGX - Quest Diagnostics Incorporated | HOLD | 0 @ USD 189.69 | USD 0 | The current share valuation price of DGX based on adjusted close was USD 189.69. The average price that DGX shares were previous bought at was USD 180.731. The current market price is 5.0% higher than average price they were purchased at. The value of the holding in DGX has fallen by USD 5,953 compared to the previous valuation of Quest Diagnostics Incorporated |
| DHR - Danaher Corporation | HOLD | 0 @ USD 228.46 | USD 0 | The current share valuation price of DHR based on adjusted close was USD 228.46. The average price that DHR shares were previous bought at was USD 209.968. The current market price is 8.8% higher than average price they were purchased at. The value of the holding in DHR has fallen by USD 106,202 compared to the previous valuation of Danaher Corporation |
| DHR - Danaher Corporation | HOLD | 0 @ USD 228.46 | USD 0 | The current share valuation price of DHR based on adjusted close was USD 228.46. The average price that DHR shares were previous bought at was USD 209.968. The current market price is 8.8% higher than average price they were purchased at. The value of the holding in DHR has fallen by USD 106,202 compared to the previous valuation of Danaher Corporation |
| DIM.PA - Sartorius Stedim Biotech | HOLD | 0 @ EUR 232.843 | EUR 0 | The current share valuation price of DIM.PA based on adjusted close was EUR 232.843. The average price that DIM.PA shares were previous bought at was EUR 220.814. The current market price is 5.4% higher than average price they were purchased at. The value of the holding in DIM.PA has fallen by EUR 1,781 (USD $2,060) compared to the previous valuation of Sartorius Stedim Biotech |
| DXCM - DexCom Inc | HOLD | 0 @ USD 62.53 | USD 0 | The current share valuation price of DXCM based on adjusted close was USD 62.53. The average price that DXCM shares were previous bought at was USD 69.4664. The current market price is -10.0% lower than average price they were purchased at. The value of the holding in DXCM has increased by USD 9,638 compared to the previous valuation of DexCom Inc however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| EL.PA - EssilorLuxottica SA | HOLD | 0 @ EUR 362.883 | EUR 0 | The current share valuation price of EL.PA based on adjusted close was EUR 362.883. The average price that EL.PA shares were previous bought at was EUR 342.762. The current market price is 5.9% higher than average price they were purchased at. The value of the holding in EL.PA has increased by EUR 134,419 (USD $155,453) compared to the previous valuation of EssilorLuxottica SA however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| ELV - Elevance Health Inc | HOLD | 0 @ USD 338.52 | USD 0 | The current share valuation price of ELV based on adjusted close was USD 338.52. The average price that ELV shares were previous bought at was USD 335.766. The current market price is 0.8% higher than average price they were purchased at. The value of the holding in ELV has increased by USD 77,407 compared to the previous valuation of Elevance Health Inc however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| ELV - Elevance Health Inc | HOLD | 0 @ USD 338.52 | USD 0 | The current share valuation price of ELV based on adjusted close was USD 338.52. The average price that ELV shares were previous bought at was USD 335.766. The current market price is 0.8% higher than average price they were purchased at. The value of the holding in ELV has increased by USD 77,407 compared to the previous valuation of Elevance Health Inc however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| ERF.PA - Eurofins Scientific SE | HOLD | 0 @ EUR 68.4506 | EUR 0 | The current share valuation price of ERF.PA based on adjusted close was EUR 68.4506. The average price that ERF.PA shares were previous bought at was EUR 69.3899. The current market price is -1.4% lower than average price they were purchased at. The value of the holding in ERF.PA has increased by EUR 867 (USD $1,003) compared to the previous valuation of Eurofins Scientific SE however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| EW - Edwards Lifesciences Corp | HOLD | 0 @ USD 86.75 | USD 0 | The current share valuation price of EW based on adjusted close was USD 86.75. The average price that EW shares were previous bought at was USD 78.715. The current market price is 10.2% higher than average price they were purchased at. The value of the holding in EW has fallen by USD 6,603 compared to the previous valuation of Edwards Lifesciences Corp |
| FME.DE - Fresenius Medical Care AG | HOLD | 0 @ EUR 47.774 | EUR 0 | The current share valuation price of FME.DE based on adjusted close was EUR 47.774. The average price that FME.DE shares were previous bought at was EUR 50.9587. The current market price is -6.2% lower than average price they were purchased at. The value of the holding in FME.DE has fallen by EUR 2,211 (USD $2,557) compared to the previous valuation of Fresenius Medical Care AG |
| FPH.NZ - | HOLD | 0 @ NZD 21.8477 | NZD 0 | The current share valuation price of FPH.NZ based on adjusted close was NZD 21.8477. The average price that FPH.NZ shares were previous bought at was NZD 21.1253. The current market price is 3.4% higher than average price they were purchased at. The value of the holding in FPH.NZ has increased by NZD 14,667 (USD $8,249) compared to the previous valuation of however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| FRE.DE - Fresenius SE & Co KGaA | HOLD | 0 @ EUR 54.925 | EUR 0 | The current share valuation price of FRE.DE based on adjusted close was EUR 54.925. The average price that FRE.DE shares were previous bought at was EUR 52.4017. The current market price is 4.8% higher than average price they were purchased at. The value of the holding in FRE.DE has fallen by EUR 1,676 (USD $1,938) compared to the previous valuation of Fresenius SE & Co KGaA |
| GALD.SW - | HOLD | 0 @ CHF 196.86 | CHF 0 | The current share valuation price of GALD.SW based on adjusted close was CHF 196.86. The average price that GALD.SW shares were previous bought at was CHF 184.4. The current market price is 6.8% higher than average price they were purchased at. The value of the holding in GALD.SW has increased by CHF 41,085 (USD $50,849) compared to the previous valuation of however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| GEHC - GE HealthCare Technologies Inc. | HOLD | 0 @ USD 80.6301 | USD 0 | The current share valuation price of GEHC based on adjusted close was USD 80.6301. The average price that GEHC shares were previous bought at was USD 75.4292. The current market price is 6.9% higher than average price they were purchased at. The value of the holding in GEHC has increased by USD 6,399 compared to the previous valuation of GE HealthCare Technologies Inc. however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| GILD - Guild Esports Plc | HOLD | 0 @ USD 127.51 | USD 0 | The current share valuation price of GILD based on adjusted close was USD 127.51. The average price that GILD shares were previous bought at was USD 116.15. The current market price is 9.8% higher than average price they were purchased at. The value of the holding in GILD has increased by USD 56,310 compared to the previous valuation of Guild Esports Plc however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| GMAB.CO - | HOLD | 0 @ DKK 318.436 | DKK 0 | The current share valuation price of GMAB.CO based on adjusted close was DKK 318.436. The average price that GMAB.CO shares were previous bought at was DKK 280.97. The current market price is 13.3% higher than average price they were purchased at. The value of the holding in GMAB.CO has increased by DKK 107,960 (USD $16,716) compared to the previous valuation of however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| GRF.MC - Grifols SA | HOLD | 0 @ EUR 12.1463 | EUR 0 | The current share valuation price of GRF.MC based on adjusted close was EUR 12.1463. The average price that GRF.MC shares were previous bought at was EUR 13.2076. The current market price is -8.0% lower than average price they were purchased at. The value of the holding in GRF.MC has increased by EUR 4,226 (USD $4,887) compared to the previous valuation of Grifols SA however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| GSK.L - GlaxoSmithKline PLC | HOLD | 0 @ GBP 23.9947 | GBP 0 | The current share valuation price of GSK.L based on adjusted close was GBP 23.9947. The average price that GSK.L shares were previous bought at was GBP 23.2527. The current market price is 3.2% higher than average price they were purchased at. The value of the holding in GSK.L has increased by GBP 71,385 (USD $93,933) compared to the previous valuation of GlaxoSmithKline PLC however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| HCA - HCA Holdings Inc | HOLD | 0 @ USD 514.76 | USD 0 | The current share valuation price of HCA based on adjusted close was USD 514.76. The average price that HCA shares were previous bought at was USD 438.288. The current market price is 17.4% higher than average price they were purchased at. The value of the holding in HCA has fallen by USD 4,373 compared to the previous valuation of HCA Holdings Inc |
| HIK.L - | HOLD | 0 @ GBP 20.6349 | GBP 0 | The current share valuation price of HIK.L based on adjusted close was GBP 20.6349. The average price that HIK.L shares were previous bought at was GBP 22.9595. The current market price is -10.1% lower than average price they were purchased at. The value of the holding in HIK.L has fallen by GBP 6,127 (USD $8,062) compared to the previous valuation of |
| HLN.L - Haleon PLC | HOLD | 0 @ GBP 4.90476 | GBP 0 | The current share valuation price of HLN.L based on adjusted close was GBP 4.90476. The average price that HLN.L shares were previous bought at was GBP 4.88935. The current market price is 0.3% higher than average price they were purchased at. The value of the holding in HLN.L has fallen by GBP 9,020 (USD $11,869) compared to the previous valuation of Haleon PLC |
| HOLX - Hologic Inc | HOLD | 0 @ USD 74.8 | USD 0 | The current share valuation price of HOLX based on adjusted close was USD 74.8. The average price that HOLX shares were previous bought at was USD 69.7374. The current market price is 7.3% higher than average price they were purchased at. The value of the holding in HOLX has fallen by USD 6,149 compared to the previous valuation of Hologic Inc |
| HUM - Hummingbird Resources PLC | HOLD | 0 @ USD 245.99 | USD 0 | The current share valuation price of HUM based on adjusted close was USD 245.99. The average price that HUM shares were previous bought at was USD 267.564. The current market price is -8.1% lower than average price they were purchased at. The value of the holding in HUM has increased by USD 139,898 compared to the previous valuation of Hummingbird Resources PLC however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| HUM - Humana Inc | HOLD | 0 @ USD 245.99 | USD 0 | The current share valuation price of HUM based on adjusted close was USD 245.99. The average price that HUM shares were previous bought at was USD 267.564. The current market price is -8.1% lower than average price they were purchased at. The value of the holding in HUM has increased by USD 139,898 compared to the previous valuation of Humana Inc however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| IDXX - IDEXX Laboratories Inc | HOLD | 0 @ USD 755.96 | USD 0 | The current share valuation price of IDXX based on adjusted close was USD 755.96. The average price that IDXX shares were previous bought at was USD 609.637. The current market price is 24.0% higher than average price they were purchased at. The value of the holding in IDXX has fallen by USD 160,339 compared to the previous valuation of IDEXX Laboratories Inc |
| ILMN - Illumina Inc | HOLD | 0 @ USD 129.81 | USD 0 | The current share valuation price of ILMN based on adjusted close was USD 129.81. The average price that ILMN shares were previous bought at was USD 102.955. The current market price is 26.1% higher than average price they were purchased at. The value of the holding in ILMN has increased by USD 538 compared to the previous valuation of Illumina Inc however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| INCY - Incyte Corporation | HOLD | 0 @ USD 105.65 | USD 0 | The current share valuation price of INCY based on adjusted close was USD 105.65. The average price that INCY shares were previous bought at was USD 103.737. The current market price is 1.8% higher than average price they were purchased at. The value of the holding in INCY has increased by USD 1,217 compared to the previous valuation of Incyte Corporation however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| INSM - Insmed Inc | HOLD | 0 @ USD 204.51 | USD 0 | |
| IPN.PA - Ipsen SA | HOLD | 0 @ EUR 144.875 | EUR 0 | The current share valuation price of IPN.PA based on adjusted close was EUR 144.875. The average price that IPN.PA shares were previous bought at was EUR 135.691. The current market price is 6.8% higher than average price they were purchased at. The value of the holding in IPN.PA has fallen by EUR 6,737 (USD $7,791) compared to the previous valuation of Ipsen SA |
| IQV - IQVIA Holdings Inc | HOLD | 0 @ USD 231.8 | USD 0 | The current share valuation price of IQV based on adjusted close was USD 231.8. The average price that IQV shares were previous bought at was USD 195.252. The current market price is 18.7% higher than average price they were purchased at. The value of the holding in IQV has fallen by USD 4,909 compared to the previous valuation of IQVIA Holdings Inc |
| ISRG - Intuitive Surgical Inc | HOLD | 0 @ USD 574.23 | USD 0 | The current share valuation price of ISRG based on adjusted close was USD 574.23. The average price that ISRG shares were previous bought at was USD 538.222. The current market price is 6.7% higher than average price they were purchased at. The value of the holding in ISRG has fallen by USD 112,358 compared to the previous valuation of Intuitive Surgical Inc |
| JNJ - Johnson & Johnson | HOLD | 0 @ USD 207.56 | USD 0 | The current share valuation price of JNJ based on adjusted close was USD 207.56. The average price that JNJ shares were previous bought at was USD 169.389. The current market price is 22.5% higher than average price they were purchased at. The value of the holding in JNJ has increased by USD 133,438 compared to the previous valuation of Johnson & Johnson however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| LH - Laboratory Corporation of America Holdings | HOLD | 0 @ USD 268.27 | USD 0 | The current share valuation price of LH based on adjusted close was USD 268.27. The average price that LH shares were previous bought at was USD 262.51. The current market price is 2.2% higher than average price they were purchased at. The value of the holding in LH has fallen by USD 2,669 compared to the previous valuation of Laboratory Corporation of America Holdings |
| LLY - Eli Lilly and Company | HOLD | 0 @ USD 1104.34 | USD 0 | The current share valuation price of LLY based on adjusted close was USD 1104.34. The average price that LLY shares were previous bought at was USD 835.036. The current market price is 32.3% higher than average price they were purchased at. The value of the holding in LLY has fallen by USD 365,148 compared to the previous valuation of Eli Lilly and Company |
| LONN.SW - | HOLD | 0 @ CHF 671.507 | CHF 0 | The current share valuation price of LONN.SW based on adjusted close was CHF 671.507. The average price that LONN.SW shares were previous bought at was CHF 676.753. The current market price is -0.8% lower than average price they were purchased at. The value of the holding in LONN.SW has increased by CHF 6,764 (USD $8,371) compared to the previous valuation of however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| MCK - McKesson Corporation | HOLD | 0 @ USD 883.71 | USD 0 | The current share valuation price of MCK based on adjusted close was USD 883.71. The average price that MCK shares were previous bought at was USD 778.024. The current market price is 13.6% higher than average price they were purchased at. The value of the holding in MCK has fallen by USD 85,812 compared to the previous valuation of McKesson Corporation |
| MDT - Medtronic PLC | HOLD | 0 @ USD 105.02 | USD 0 | The current share valuation price of MDT based on adjusted close was USD 105.02. The average price that MDT shares were previous bought at was USD 97.2856. The current market price is 8.0% higher than average price they were purchased at. The value of the holding in MDT has fallen by USD 11,077 compared to the previous valuation of Medtronic PLC |
| MRK - Marks Electrical Group PLC | HOLD | 0 @ USD 104.63 | USD 0 | The current share valuation price of MRK based on adjusted close was USD 104.63. The average price that MRK shares were previous bought at was USD 84.0604. The current market price is 24.5% higher than average price they were purchased at. The value of the holding in MRK has fallen by USD 178,120 compared to the previous valuation of Marks Electrical Group PLC |
| MRK - Merck & Company Inc | HOLD | 0 @ USD 104.63 | USD 0 | The current share valuation price of MRK based on adjusted close was USD 104.63. The average price that MRK shares were previous bought at was USD 84.0604. The current market price is 24.5% higher than average price they were purchased at. The value of the holding in MRK has fallen by USD 178,120 compared to the previous valuation of Merck & Company Inc |
| MRK.DE - Merck KGaA | HOLD | 0 @ EUR 134.154 | EUR 0 | The current share valuation price of MRK.DE based on adjusted close was EUR 134.154. The average price that MRK.DE shares were previous bought at was EUR 130.447. The current market price is 2.8% higher than average price they were purchased at. The value of the holding in MRK.DE has increased by EUR 1,887 (USD $2,182) compared to the previous valuation of Merck KGaA however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| MTD - Mettler-Toledo International Inc | HOLD | 0 @ USD 1486.55 | USD 0 | The current share valuation price of MTD based on adjusted close was USD 1486.55. The average price that MTD shares were previous bought at was USD 1463.69. The current market price is 1.6% higher than average price they were purchased at. The value of the holding in MTD has fallen by USD 44,781 compared to the previous valuation of Mettler-Toledo International Inc |
| MTD - AMUNDI EUR GOV 710 | HOLD | 0 @ USD 1486.55 | USD 0 | The current share valuation price of MTD based on adjusted close was USD 1486.55. The average price that MTD shares were previous bought at was USD 1463.69. The current market price is 1.6% higher than average price they were purchased at. The value of the holding in MTD has fallen by USD 44,781 compared to the previous valuation of AMUNDI EUR GOV 710 |
| NBIX - Neurocrine Biosciences Inc | HOLD | 0 @ USD 151.58 | USD 0 | The current share valuation price of NBIX based on adjusted close was USD 151.58. The average price that NBIX shares were previous bought at was USD 140.213. The current market price is 8.1% higher than average price they were purchased at. The value of the holding in NBIX has increased by USD 15,037 compared to the previous valuation of Neurocrine Biosciences Inc however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| NOVN.SW - | HOLD | 0 @ CHF 130.702 | CHF 0 | The current share valuation price of NOVN.SW based on adjusted close was CHF 130.702. The average price that NOVN.SW shares were previous bought at was CHF 123.74. The current market price is 5.6% higher than average price they were purchased at. The value of the holding in NOVN.SW has increased by CHF 304,631 (USD $377,028) compared to the previous valuation of however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| NOVO-B.CO - Novo Nordisk A/S | HOLD | 0 @ DKK 48.7585 | DKK 0 | The current share valuation price of NOVO-B.CO based on adjusted close was DKK 48.7585. The average price that NOVO-B.CO shares were previous bought at was DKK 55.9384. The current market price is -12.8% lower than average price they were purchased at. The value of the holding in NOVO-B.CO has increased by DKK 681,479 (USD $105,519) compared to the previous valuation of Novo Nordisk A/S however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| NTRA - Natera Inc | HOLD | 0 @ USD 237.12 | USD 0 | The current share valuation price of NTRA based on adjusted close was USD 237.12. The average price that NTRA shares were previous bought at was USD 173.306. The current market price is 36.8% higher than average price they were purchased at. The value of the holding in NTRA has increased by USD 1,952 compared to the previous valuation of Natera Inc however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| ORNBV.HE - Orion Oyj | HOLD | 0 @ EUR 70.6411 | EUR 0 | The current share valuation price of ORNBV.HE based on adjusted close was EUR 70.6411. The average price that ORNBV.HE shares were previous bought at was EUR 67.8405. The current market price is 4.1% higher than average price they were purchased at. The value of the holding in ORNBV.HE has increased by EUR 4,464 (USD $5,163) compared to the previous valuation of Orion Oyj however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| PFE - Pfizer Inc | HOLD | 0 @ USD 25.71 | USD 0 | The current share valuation price of PFE based on adjusted close was USD 25.71. The average price that PFE shares were previous bought at was USD 24.7625. The current market price is 3.8% higher than average price they were purchased at. The value of the holding in PFE has fallen by USD 2,520 compared to the previous valuation of Pfizer Inc |
| PHIA.AS - Koninklijke Philips NV | HOLD | 0 @ EUR 28.1174 | EUR 0 | The current share valuation price of PHIA.AS based on adjusted close was EUR 28.1174. The average price that PHIA.AS shares were previous bought at was EUR 26.5139. The current market price is 6.0% higher than average price they were purchased at. The value of the holding in PHIA.AS has increased by EUR 5,728 (USD $6,624) compared to the previous valuation of Koninklijke Philips NV however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| PME.AX - | HOLD | 0 @ AUD 170.197 | AUD 0 | The current share valuation price of PME.AX based on adjusted close was AUD 170.197. The average price that PME.AX shares were previous bought at was AUD 181.215. The current market price is -6.1% lower than average price they were purchased at. The value of the holding in PME.AX has increased by AUD 3,751 (USD $2,427) compared to the previous valuation of however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| PODD - Insulet Corporation | HOLD | 0 @ USD 326.8 | USD 0 | The current share valuation price of PODD based on adjusted close was USD 326.8. The average price that PODD shares were previous bought at was USD 333.441. The current market price is -2.0% lower than average price they were purchased at. The value of the holding in PODD has fallen by USD 6,078 compared to the previous valuation of Insulet Corporation |
| QIA.DE - QIAGEN NV | HOLD | 0 @ EUR 48.4172 | EUR 0 | The current share valuation price of QIA.DE based on adjusted close was EUR 48.4172. The average price that QIA.DE shares were previous bought at was EUR 45.759. The current market price is 5.8% higher than average price they were purchased at. The value of the holding in QIA.DE has increased by EUR 8,482 (USD $9,809) compared to the previous valuation of QIAGEN NV however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| REC.MI - Recordati Industria Chimica e Farmaceutica SpA | HOLD | 0 @ EUR 58.5874 | EUR 0 | The current share valuation price of REC.MI based on adjusted close was EUR 58.5874. The average price that REC.MI shares were previous bought at was EUR 58.4515. The current market price is 0.2% higher than average price they were purchased at. The value of the holding in REC.MI has fallen by EUR 164 (USD $190) compared to the previous valuation of Recordati Industria Chimica e Farmaceutica SpA |
| REGN - Regeneron Pharmaceuticals Inc | HOLD | 0 @ USD 784.61 | USD 0 | The current share valuation price of REGN based on adjusted close was USD 784.61. The average price that REGN shares were previous bought at was USD 712.428. The current market price is 10.1% higher than average price they were purchased at. The value of the holding in REGN has fallen by USD 18,239 compared to the previous valuation of Regeneron Pharmaceuticals Inc |
| RMD - ResMed Inc | HOLD | 0 @ USD 255.04 | USD 0 | The current share valuation price of RMD based on adjusted close was USD 255.04. The average price that RMD shares were previous bought at was USD 256.073. The current market price is -0.4% lower than average price they were purchased at. The value of the holding in RMD has fallen by USD 3,100 compared to the previous valuation of ResMed Inc |
| RO.SW - | HOLD | 0 @ CHF 403.153 | CHF 0 | The current share valuation price of RO.SW based on adjusted close was CHF 403.153. The average price that RO.SW shares were previous bought at was CHF 343.117. The current market price is 17.5% higher than average price they were purchased at. The value of the holding in RO.SW has increased by CHF 8,562 (USD $10,597) compared to the previous valuation of however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| ROG.SW - | HOLD | 0 @ CHF 388.382 | CHF 0 | The current share valuation price of ROG.SW based on adjusted close was CHF 388.382. The average price that ROG.SW shares were previous bought at was CHF 359.664. The current market price is 8.0% higher than average price they were purchased at. The value of the holding in ROG.SW has increased by CHF 8,589 (USD $10,630) compared to the previous valuation of however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| RPRX - Royalty Pharma Plc | HOLD | 0 @ USD 39.84 | USD 0 | The current share valuation price of RPRX based on adjusted close was USD 39.84. The average price that RPRX shares were previous bought at was USD 36.7765. The current market price is 8.3% higher than average price they were purchased at. The value of the holding in RPRX has increased by USD 2,478 compared to the previous valuation of Royalty Pharma Plc however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| SAN.PA - Sanofi SA | HOLD | 0 @ EUR 99.9406 | EUR 0 | The current share valuation price of SAN.PA based on adjusted close was EUR 99.9406. The average price that SAN.PA shares were previous bought at was EUR 99.0472. The current market price is 0.9% higher than average price they were purchased at. The value of the holding in SAN.PA has increased by EUR 2,820 (USD $3,261) compared to the previous valuation of Sanofi SA however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| SDZ.SW - | HOLD | 0 @ CHF 69.7077 | CHF 0 | The current share valuation price of SDZ.SW based on adjusted close was CHF 69.7077. The average price that SDZ.SW shares were previous bought at was CHF 57.9682. The current market price is 20.3% higher than average price they were purchased at. The value of the holding in SDZ.SW has increased by CHF 4,470 (USD $5,532) compared to the previous valuation of however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| SHL.AX - | HOLD | 0 @ AUD 15.2204 | AUD 0 | The current share valuation price of SHL.AX based on adjusted close was AUD 15.2204. The average price that SHL.AX shares were previous bought at was AUD 15.0663. The current market price is 1.0% higher than average price they were purchased at. The value of the holding in SHL.AX has increased by AUD 5,520 (USD $3,572) compared to the previous valuation of however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| SHL.DE - Siemens Healthineers AG | HOLD | 0 @ EUR 49.0953 | EUR 0 | The current share valuation price of SHL.DE based on adjusted close was EUR 49.0953. The average price that SHL.DE shares were previous bought at was EUR 53.4708. The current market price is -8.2% lower than average price they were purchased at. The value of the holding in SHL.DE has fallen by EUR 565 (USD $653) compared to the previous valuation of Siemens Healthineers AG |
| SIG.AX - | HOLD | 0 @ AUD 1.90092 | AUD 0 | The current share valuation price of SIG.AX based on adjusted close was AUD 1.90092. The average price that SIG.AX shares were previous bought at was AUD 1.89691. The current market price is 0.2% higher than average price they were purchased at. The value of the holding in SIG.AX has increased by AUD 16,231 (USD $10,502) compared to the previous valuation of however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| SN.L - Smith & Nephew PLC | HOLD | 0 @ GBP 16.7063 | GBP 0 | The current share valuation price of SN.L based on adjusted close was GBP 16.7063. The average price that SN.L shares were previous bought at was GBP 17.294. The current market price is -3.4% lower than average price they were purchased at. The value of the holding in SN.L has increased by GBP 1,336 (USD $1,758) compared to the previous valuation of Smith & Nephew PLC however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| SOBI.ST - | HOLD | 0 @ SEK 35.8946 | SEK 0 | The current share valuation price of SOBI.ST based on adjusted close was SEK 35.8946. The average price that SOBI.ST shares were previous bought at was SEK 32.9135. The current market price is 9.1% higher than average price they were purchased at. The value of the holding in SOBI.ST has increased by SEK 4,806 (USD $504) compared to the previous valuation of however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| SOLV - Solventum Corp. | HOLD | 0 @ USD 85.2701 | USD 0 | The current share valuation price of SOLV based on adjusted close was USD 85.2701. The average price that SOLV shares were previous bought at was USD 72.4742. The current market price is 17.7% higher than average price they were purchased at. The value of the holding in SOLV has fallen by USD 1,925 compared to the previous valuation of Solventum Corp. |
| SOON.SW - | HOLD | 0 @ CHF 247.192 | CHF 0 | The current share valuation price of SOON.SW based on adjusted close was CHF 247.192. The average price that SOON.SW shares were previous bought at was CHF 275.476. The current market price is -10.3% lower than average price they were purchased at. The value of the holding in SOON.SW has increased by CHF 30,120 (USD $37,278) compared to the previous valuation of however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| SRT3.DE - Sartorius AG | HOLD | 0 @ EUR 280.362 | EUR 0 | The current share valuation price of SRT3.DE based on adjusted close was EUR 280.362. The average price that SRT3.DE shares were previous bought at was EUR 254.653. The current market price is 10.1% higher than average price they were purchased at. The value of the holding in SRT3.DE has fallen by EUR 5,531 (USD $6,397) compared to the previous valuation of Sartorius AG |
| STE - STERIS plc | HOLD | 0 @ USD 266.85 | USD 0 | The current share valuation price of STE based on adjusted close was USD 266.85. The average price that STE shares were previous bought at was USD 240.814. The current market price is 10.8% higher than average price they were purchased at. The value of the holding in STE has fallen by USD 30,701 compared to the previous valuation of STERIS plc |
| STMN.SW - | HOLD | 0 @ CHF 117.594 | CHF 0 | The current share valuation price of STMN.SW based on adjusted close was CHF 117.594. The average price that STMN.SW shares were previous bought at was CHF 121.695. The current market price is -3.4% lower than average price they were purchased at. The value of the holding in STMN.SW has fallen by CHF 15,046 (USD $18,622) compared to the previous valuation of |
| SYK - Stryker Corporation | HOLD | 0 @ USD 372.29 | USD 0 | The current share valuation price of SYK based on adjusted close was USD 372.29. The average price that SYK shares were previous bought at was USD 370.329. The current market price is 0.5% higher than average price they were purchased at. The value of the holding in SYK has fallen by USD 43,728 compared to the previous valuation of Stryker Corporation |
| TEVA - Teva Pharma Industries Ltd ADR | HOLD | 0 @ USD 26.32 | USD 0 | The current share valuation price of TEVA based on adjusted close was USD 26.32. The average price that TEVA shares were previous bought at was USD 19.0228. The current market price is 38.4% higher than average price they were purchased at. The value of the holding in TEVA has increased by USD 33,401 compared to the previous valuation of Teva Pharma Industries Ltd ADR however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| TMO - Time Out Group plc | HOLD | 0 @ USD 593.25 | USD 0 | The current share valuation price of TMO based on adjusted close was USD 593.25. The average price that TMO shares were previous bought at was USD 477.707. The current market price is 24.2% higher than average price they were purchased at. The value of the holding in TMO has fallen by USD 97,612 compared to the previous valuation of Time Out Group plc |
| UCB.BR - UCB SA | HOLD | 0 @ EUR 275.61 | EUR 0 | The current share valuation price of UCB.BR based on adjusted close was EUR 275.61. The average price that UCB.BR shares were previous bought at was EUR 248.44. The current market price is 10.9% higher than average price they were purchased at. The value of the holding in UCB.BR has increased by EUR 55,797 (USD $64,528) compared to the previous valuation of UCB SA however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| UNH - UnitedHealth Group Incorporated | HOLD | 0 @ USD 329.71 | USD 0 | The current share valuation price of UNH based on adjusted close was USD 329.71. The average price that UNH shares were previous bought at was USD 320.557. The current market price is 2.9% higher than average price they were purchased at. The value of the holding in UNH has increased by USD 233,442 compared to the previous valuation of UnitedHealth Group Incorporated however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| UTHR - United Therapeutics Corporation | HOLD | 0 @ USD 488.43 | USD 0 | The current share valuation price of UTHR based on adjusted close was USD 488.43. The average price that UTHR shares were previous bought at was USD 419.012. The current market price is 16.6% higher than average price they were purchased at. The value of the holding in UTHR has increased by USD 2,418 compared to the previous valuation of United Therapeutics Corporation however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| VEEV - Veeva Systems Inc Class A | HOLD | 0 @ USD 240.67 | USD 0 | The current share valuation price of VEEV based on adjusted close was USD 240.67. The average price that VEEV shares were previous bought at was USD 284.797. The current market price is -15.5% lower than average price they were purchased at. The value of the holding in VEEV has increased by USD 19,772 compared to the previous valuation of Veeva Systems Inc Class A however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| VRTX - Vertex Pharmaceuticals Inc | HOLD | 0 @ USD 432.17 | USD 0 | The current share valuation price of VRTX based on adjusted close was USD 432.17. The average price that VRTX shares were previous bought at was USD 423.38. The current market price is 2.1% higher than average price they were purchased at. The value of the holding in VRTX has increased by USD 72,521 compared to the previous valuation of Vertex Pharmaceuticals Inc however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| WAT - Waters Corporation | HOLD | 0 @ USD 407.14 | USD 0 | The current share valuation price of WAT based on adjusted close was USD 407.14. The average price that WAT shares were previous bought at was USD 337.329. The current market price is 20.7% higher than average price they were purchased at. The value of the holding in WAT has fallen by USD 84,423 compared to the previous valuation of Waters Corporation |
| WAT - MULETFWATIMETFP | HOLD | 0 @ USD 407.14 | USD 0 | The current share valuation price of WAT based on adjusted close was USD 407.14. The average price that WAT shares were previous bought at was USD 337.329. The current market price is 20.7% higher than average price they were purchased at. The value of the holding in WAT has fallen by USD 84,423 compared to the previous valuation of MULETFWATIMETFP |
| WST - West Pharmaceutical Services Inc | HOLD | 0 @ USD 277.14 | USD 0 | The current share valuation price of WST based on adjusted close was USD 277.14. The average price that WST shares were previous bought at was USD 264.273. The current market price is 4.9% higher than average price they were purchased at. The value of the holding in WST has fallen by USD 5,613 compared to the previous valuation of West Pharmaceutical Services Inc |
| ZBH - Zimmer Biomet Holdings Inc | HOLD | 0 @ USD 97.55 | USD 0 | The current share valuation price of ZBH based on adjusted close was USD 97.55. The average price that ZBH shares were previous bought at was USD 97.2797. The current market price is 0.3% higher than average price they were purchased at. The value of the holding in ZBH has increased by USD 2,039 compared to the previous valuation of Zimmer Biomet Holdings Inc however if the holding was sold on 2025-11-26 this would crystalise an overall loss. |
| ZTS - Zoetis Inc | HOLD | 0 @ USD 127.69 | USD 0 | The current share valuation price of ZTS based on adjusted close was USD 127.69. The average price that ZTS shares were previous bought at was USD 139.124. The current market price is -8.2% lower than average price they were purchased at. The value of the holding in ZTS has fallen by USD 17,313 compared to the previous valuation of Zoetis Inc |